Weiyang Tao
Overview
Explore the profile of Weiyang Tao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
3069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao W, Li X, Guan J, Yan S, Teng L, Sun X, et al.
Discov Oncol
. 2025 Jan;
16(1):48.
PMID: 39812959
Cancer vaccines are promising as an effective means of stimulating the immune system to clear tumors as well as to establish immune surveillance. In this paper, we discuss the main...
2.
Tao W, Sinha A, Raddassi K, Pandit A
Front Immunol
. 2024 Oct;
15:1414400.
PMID: 39445014
High-dimensional cell phenotyping is a powerful tool to study molecular and cellular changes in health and diseases. CyTOF enables high-dimensional cell phenotyping using tens of surface and intra-cellular markers. To...
3.
Li G, Ma X, Sui S, Chen Y, Li H, Liu L, et al.
J Exp Clin Cancer Res
. 2024 Oct;
43(1):278.
PMID: 39363363
Background: N4-Acetylcytidine (ac4C), a highly conserved post-transcriptional mechanism, plays a pivotal role in RNA modification and tumor progression. However, the molecular mechanism by which ac4C modification mediates tumor immunosuppression remains...
4.
Yan S, Zhao W, Dong Y, Wang H, Xu S, Yu T, et al.
World J Surg Oncol
. 2024 Sep;
22(1):248.
PMID: 39267055
Background: The novel anti-HER2 antibody drug conjugates (ADCs) can effectively improve the long-term survival of patients with HER2-low expression breast cancer. However, pathological responses to neoadjuvant therapy (NAT) within HER2-low...
5.
Teng L, Du J, Yan S, Xu P, Liu J, Zhao X, et al.
Breast Cancer
. 2024 May;
31(5):769-786.
PMID: 38802681
Introduction: The axillary lymph node status (ALNS) and internal mammary lymph nodes (IMLN) expression associated with breast cancer are closely linked to prognosis. This study aimed to establish a nomogram...
6.
Yan S, Teng L, Du J, Ji L, Xu P, Zhao W, et al.
Mol Med Rep
. 2024 Apr;
29(6).
PMID: 38577930
Emerging scientific evidence has suggested that the long non‑coding (lnc)RNA differentiation antagonizing non‑protein coding RNA () serves a significant role in human tumorigenesis and cancer progression; however, the precise mechanism...
7.
Liu J, Yan S, Du J, Teng L, Yang R, Xu P, et al.
Heliyon
. 2024 Mar;
10(6):e27531.
PMID: 38501021
Tyrosine kinase inhibitors (TKIs) have become first-line drugs for cancer treatment. However, their clinical use is seriously hindered since many patients experience diarrhea after receiving TKIs. The mechanisms of TKI-associated...
8.
van der Heijden E, Blokland S, Hillen M, Lopes A, van Vliet-Moret F, Rosenberg A, et al.
Lancet Rheumatol
. 2024 Jan;
2(5):e260-e269.
PMID: 38273473
Background: Primary Sjögren's syndrome is a systemic autoimmune disease characterised by secretory gland dysfunction, for which no effective therapy is available. Based on the complementary properties of leflunomide and hydroxychloroquine...
9.
Deng J, Leijten E, Zhu Y, Nordkamp M, Ye S, Pouw J, et al.
J Dermatol Sci
. 2023 Aug;
111(3):101-108.
PMID: 37543503
Background: Psoriasis is an immune-mediated inflammatory skin disease. Psoriasis severity evaluation is important for clinicians in the assessment of disease severity and subsequent clinical decision making. However, no objective biomarker...
10.
Teng L, Yan S, Du J, Yang R, Xu P, Tao W
World J Surg Oncol
. 2023 May;
21(1):144.
PMID: 37158932
Introduction: Breast angiosarcoma is a rare malignancy of endovascular origin, accounting for less than 1% of all mammary cancers. Our aim was to explore clinicopathological features and the factors associated...